Background
Transcatheter aortic valve implantation (TAVI) has become a method of choice in repair of valvular aortic stenosis, especially in group of patients with high surgical risk.
Aim
The objective was to evaluate the immediate and midterm results of applying TAVI in aortic valve surgery.
Methods 80 patients with a median age of 78 ± 5.2 years were included. All patients had severe aortic stenosis. According to the echo an average gradient of systolic pressure on the aortic valve was >20% by EuroSCORE and > 10% by STS. We have implanted Edwards Sapiens/Sapiens XT or Medtronic CoreValve bioprostheses. In 58 cases implantation was performed through transfemoral access (including 30 Edwards Sapien cases) and in 17 cases-transapical access was used due to vascular abnormalities. In the rest 5 patients we used direct transaortic (4 cases) and in 1 casetranssubclavian approach.
Results
Intraoperative mortality was 1.25%: 1 patient (women) died with symptoms of acute heart failure. Total 30 days mortality rate was 5%: 2 patients died within 7 days after TAVI -IM and other 2 patients developed cardiogenic shock. Incidence of non-fatal stroke was 2.5%. In 2 patients the procedure of hemodialysis needed to be performed because of acute contrast-induced renal injury. Other patients had no significant complications. The AMPG after Edwards Sapien and Medtronic Core-Valve implantations were 10,9 ± 3,5 and 14,3 ± 5,4 mm Hg respectively. The incidence of paravalvular leak of 2 degree had a tendency to be higher in CoreValve than in Edwards Sapien subgroup (15% vs. 5%). Nevertheless, by the end of 1-year follow-up only 2 patients had residual aortic regurgitation >2 degree (CoreValve). In 5 patients after CoreValve implantation (25%) -need of permanent pacemaker. The overall mortality rate by the end of 1-year was 12% with no procedure-related deaths.
Conclusion
TAVI can be considered as a real alternative to traditional aortic valve replacement in high-risk patients.
